Zomedica Unveils New Canine Tests Offering Faster Diagnostics for Heart and Breeding Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2024
0mins
Should l Buy ?
Source: Benzinga
New Canine Assays Launch: Zomedica Corp. has launched two new canine assays for its TRUFORMA In-Clinic Biosensor Testing Platform, including a progesterone test for breeding management and an NT-proBNP test for detecting heart conditions in dogs.
Veterinary Impact: The new tests provide veterinarians with rapid, accurate results, enhancing their ability to diagnose and treat reproductive and cardiac issues in dogs, ultimately improving patient care and outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
